id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-1059-0004,FDA,FDA-2019-E-1059,Determination of Regulatory Review Period for Purposes of Patent Extension; ANDEXXA,Notice,Determinations,2019-12-05T05:00:00Z,2019,12,2019-12-05T05:00:00Z,2020-06-03T03:59:59Z,2019-12-05T15:56:38Z,2019-26251,0,0,09000064841e7454
FDA-2019-E-1059-0003,FDA,FDA-2019-E-1059,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,,2019-11-01T20:36:11Z,,0,0,090000648411687e
FDA-2019-E-1059-0002,FDA,FDA-2019-E-1059,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-05-13T04:00:00Z,2019,5,2019-05-13T04:00:00Z,,2019-05-13T17:58:22Z,,0,0,0900006483c728f3
FDA-2019-E-1059-0001,FDA,FDA-2019-E-1059,"Patent Extension Application for ANDEXXA Patent No. 8,153,590",Other,Application,2019-03-06T05:00:00Z,2019,3,2019-03-06T05:00:00Z,,2019-03-06T15:26:44Z,,0,0,0900006483ac36aa